1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Market Analysis by Type
  • 1.3.1 Global Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
  • 1.3.2 Immunomodulators
  • 1.3.3 Interferons
  • 1.3.4 Decarboxylase Inhibitors
  • 1.3.5 Dopamine Agonists
  • 1.3.6 Others
• 1.4 Market by Application
  • 1.4.1 Global Neurodegenerative Disorder Therapeutics Market Share by Application: 2020 VS 2026
  • 1.4.2 Multiple Sclerosis
  • 1.4.3 Parkinson'S Disease
  • 1.4.4 Alzheimer'S Disease
  • 1.4.5 Spinal Muscular Atrophy
  • 1.4.6 Huntington Disease
  • 1.4.7 Other Neurodegenerative Disorders
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Neurodegenerative Disorder Therapeutics Market Perspective (2015-2026)
• 2.2 Neurodegenerative Disorder Therapeutics Growth Trends by Regions
  • 2.2.1 Neurodegenerative Disorder Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Neurodegenerative Disorder Therapeutics Historic Market Share by Regions (2015-2020)
  • 2.2.3 Neurodegenerative Disorder Therapeutics Forecasted Market Size by Regions (2021-2026)
• 2.3 Neurodegenerative Disorder Therapeutics Industry Dynamic
  • 2.3.1 Neurodegenerative Disorder Therapeutics Market Trends
  • 2.3.2 Neurodegenerative Disorder Therapeutics Market Drivers
  • 2.3.3 Neurodegenerative Disorder Therapeutics Market Challenges
  • 2.3.4 Neurodegenerative Disorder Therapeutics Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Neurodegenerative Disorder Therapeutics Players by Market Size
  • 3.1.1 Global Top Neurodegenerative Disorder Therapeutics Players by Revenue (2015-2020)
  • 3.1.2 Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Players (2015-2020)
• 3.2 Global Neurodegenerative Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Players Covered: Ranking by Neurodegenerative Disorder Therapeutics Revenue
• 3.4 Global Neurodegenerative Disorder Therapeutics Market Concentration Ratio
  • 3.4.1 Global Neurodegenerative Disorder Therapeutics Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Disorder Therapeutics Revenue in 2019
• 3.5 Key Players Neurodegenerative Disorder Therapeutics Area Served
• 3.6 Key Players Neurodegenerative Disorder Therapeutics Product Solution and Service
• 3.7 Date of Enter into Neurodegenerative Disorder Therapeutics Market
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Neurodegenerative Disorder Therapeutics Breakdown Data by Type

• 4.1 Global Neurodegenerative Disorder Therapeutics Historic Market Size by Type (2015-2020)
• 4.2 Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Type (2021-2026)

5 Neurodegenerative Disorder Therapeutics Breakdown Data by Application

• 5.1 Global Neurodegenerative Disorder Therapeutics Historic Market Size by Application (2015-2020)
• 5.2 Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Neurodegenerative Disorder Therapeutics Market Size (2015-2026)
• 6.2 North America Neurodegenerative Disorder Therapeutics Market Size by Type (2015-2020)
• 6.3 North America Neurodegenerative Disorder Therapeutics Market Size by Application (2015-2020)
• 6.4 North America Neurodegenerative Disorder Therapeutics Market Size by Country (2015-2020)
  • 6.4.1 United States
  • 6.4.2 Canada

7 Europe

• 7.1 Europe Neurodegenerative Disorder Therapeutics Market Size (2015-2026)
• 7.2 Europe Neurodegenerative Disorder Therapeutics Market Size by Type (2015-2020)
• 7.3 Europe Neurodegenerative Disorder Therapeutics Market Size by Application (2015-2020)
• 7.4 Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2015-2020)
  • 7.4.1 Germany
  • 7.4.2 France
  • 7.4.3 U.K.
  • 7.4.4 Italy
  • 7.4.5 Russia
  • 7.4.6 Nordic

8 Asia-Pacific

• 8.1 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size (2015-2026)
• 8.2 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Type (2015-2020)
• 8.3 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Application (2015-2020)
• 8.4 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Region (2015-2020)
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 South Korea
  • 8.4.4 Southeast Asia
  • 8.4.5 India
  • 8.4.6 Australia

9 Latin America

• 9.1 Latin America Neurodegenerative Disorder Therapeutics Market Size (2015-2026)
• 9.2 Latin America Neurodegenerative Disorder Therapeutics Market Size by Type (2015-2020)
• 9.3 Latin America Neurodegenerative Disorder Therapeutics Market Size by Application (2015-2020)
• 9.4 Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2015-2020)
  • 9.4.1 Mexico
  • 9.4.2 Brazil

10 Middle East & Africa

• 10.1 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size (2015-2026)
• 10.2 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Type (2015-2020)
• 10.3 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Application (2015-2020)
• 10.4 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Country (2015-2020)
  • 10.4.1 Turkey
  • 10.4.2 Saudi Arabia
  • 10.4.3 UAE

11Key Players Profiles

• 11.1 Biogen, Inc.
  • 11.1.1 Biogen, Inc. Company Details
  • 11.1.2 Biogen, Inc. Business Overview
  • 11.1.3 Biogen, Inc. Neurodegenerative Disorder Therapeutics Introduction
  • 11.1.4 Biogen, Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2015-2020))
  • 11.1.5 Biogen, Inc. Recent Development
• 11.2 Pfizer, Inc.
  • 11.2.1 Pfizer, Inc. Company Details
  • 11.2.2 Pfizer, Inc. Business Overview
  • 11.2.3 Pfizer, Inc. Neurodegenerative Disorder Therapeutics Introduction
  • 11.2.4 Pfizer, Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2015-2020)
  • 11.2.5 Pfizer, Inc. Recent Development
• 11.3 Novartis AG
  • 11.3.1 Novartis AG Company Details
  • 11.3.2 Novartis AG Business Overview
  • 11.3.3 Novartis AG Neurodegenerative Disorder Therapeutics Introduction
  • 11.3.4 Novartis AG Revenue in Neurodegenerative Disorder Therapeutics Business (2015-2020)
  • 11.3.5 Novartis AG Recent Development
• 11.4 Sanofi S.A.
  • 11.4.1 Sanofi S.A. Company Details
  • 11.4.2 Sanofi S.A. Business Overview
  • 11.4.3 Sanofi S.A. Neurodegenerative Disorder Therapeutics Introduction
  • 11.4.4 Sanofi S.A. Revenue in Neurodegenerative Disorder Therapeutics Business (2015-2020)
  • 11.4.5 Sanofi S.A. Recent Development
• 11.5 Teva Pharmaceutical Industries Ltd.
  • 11.5.1 Teva Pharmaceutical Industries Ltd. Company Details
  • 11.5.2 Teva Pharmaceutical Industries Ltd. Business Overview
  • 11.5.3 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Introduction
  • 11.5.4 Teva Pharmaceutical Industries Ltd. Revenue in Neurodegenerative Disorder Therapeutics Business (2015-2020)
  • 11.5.5 Teva Pharmaceutical Industries Ltd. Recent Development
• 11.6 UCB S.A.
  • 11.6.1 UCB S.A. Company Details
  • 11.6.2 UCB S.A. Business Overview
  • 11.6.3 UCB S.A. Neurodegenerative Disorder Therapeutics Introduction
  • 11.6.4 UCB S.A. Revenue in Neurodegenerative Disorder Therapeutics Business (2015-2020)
  • 11.6.5 UCB S.A. Recent Development
• 11.7 F. Hoffmann- La Roche Ltd.
  • 11.7.1 F. Hoffmann- La Roche Ltd. Company Details
  • 11.7.2 F. Hoffmann- La Roche Ltd. Business Overview
  • 11.7.3 F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Introduction
  • 11.7.4 F. Hoffmann- La Roche Ltd. Revenue in Neurodegenerative Disorder Therapeutics Business (2015-2020)
  • 11.7.5 F. Hoffmann- La Roche Ltd. Recent Development
• 11.8 H. Lundbeck
  • 11.8.1 H. Lundbeck Company Details
  • 11.8.2 H. Lundbeck Business Overview
  • 11.8.3 H. Lundbeck Neurodegenerative Disorder Therapeutics Introduction
  • 11.8.4 H. Lundbeck Revenue in Neurodegenerative Disorder Therapeutics Business (2015-2020)
  • 11.8.5 H. Lundbeck Recent Development
• 11.9 Merck KGaA
  • 11.9.1 Merck KGaA Company Details
  • 11.9.2 Merck KGaA Business Overview
  • 11.9.3 Merck KGaA Neurodegenerative Disorder Therapeutics Introduction
  • 11.9.4 Merck KGaA Revenue in Neurodegenerative Disorder Therapeutics Business (2015-2020)
  • 11.9.5 Merck KGaA Recent Development
• 11.10 GlaxoSmithKline PLC
  • 11.10.1 GlaxoSmithKline PLC Company Details
  • 11.10.2 GlaxoSmithKline PLC Business Overview
  • 11.10.3 GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Introduction
  • 11.10.4 GlaxoSmithKline PLC Revenue in Neurodegenerative Disorder Therapeutics Business (2015-2020)
  • 11.10.5 GlaxoSmithKline PLC Recent Development
• 11.11 AbbVie Inc.
  • 10.11.1 AbbVie Inc. Company Details
  • 10.11.2 AbbVie Inc. Business Overview
  • 10.11.3 AbbVie Inc. Neurodegenerative Disorder Therapeutics Introduction
  • 10.11.4 AbbVie Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2015-2020)
  • 10.11.5 AbbVie Inc. Recent Development
• 11.12 Bristol Myers Squibb Company
  • 10.12.1 Bristol Myers Squibb Company Company Details
  • 10.12.2 Bristol Myers Squibb Company Business Overview
  • 10.12.3 Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Introduction
  • 10.12.4 Bristol Myers Squibb Company Revenue in Neurodegenerative Disorder Therapeutics Business (2015-2020)
  • 10.12.5 Bristol Myers Squibb Company Recent Development
• 11.13 Boehringer Ingeiheim International GmbH
  • 10.13.1 Boehringer Ingeiheim International GmbH Company Details
  • 10.13.2 Boehringer Ingeiheim International GmbH Business Overview
  • 10.13.3 Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Introduction
  • 10.13.4 Boehringer Ingeiheim International GmbH Revenue in Neurodegenerative Disorder Therapeutics Business (2015-2020)
  • 10.13.5 Boehringer Ingeiheim International GmbH Recent Development
• 11.14 Bayer AG
  • 10.14.1 Bayer AG Company Details
  • 10.14.2 Bayer AG Business Overview
  • 10.14.3 Bayer AG Neurodegenerative Disorder Therapeutics Introduction
  • 10.14.4 Bayer AG Revenue in Neurodegenerative Disorder Therapeutics Business (2015-2020)
  • 10.14.5 Bayer AG Recent Development
• 11.15 Eisai Co., Ltd
  • 10.15.1 Eisai Co., Ltd Company Details
  • 10.15.2 Eisai Co., Ltd Business Overview
  • 10.15.3 Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Introduction
  • 10.15.4 Eisai Co., Ltd Revenue in Neurodegenerative Disorder Therapeutics Business (2015-2020)
  • 10.15.5 Eisai Co., Ltd Recent Development

12Analyst's Viewpoints/Conclusions

13Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Disclaimer

Neurodegenerative Disorder Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Neurodegenerative Disorder Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Market segment by Type, the product can be split into
Immunomodulators
Interferons
Decarboxylase Inhibitors
Dopamine Agonists
Others

Market segment by Application, split into
Multiple Sclerosis
Parkinson'S Disease
Alzheimer'S Disease
Spinal Muscular Atrophy
Huntington Disease
Other Neurodegenerative Disorders

Based on regional and country-level analysis, the Neurodegenerative Disorder Therapeutics market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE

In the competitive analysis section of the report, leading as well as prominent players of the global Neurodegenerative Disorder Therapeutics market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The key players covered in this study
Biogen, Inc.
Pfizer, Inc.
Novartis AG
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
UCB S.A.
F. Hoffmann- La Roche Ltd.
H. Lundbeck
Merck KGaA
GlaxoSmithKline PLC
AbbVie Inc.
Bristol Myers Squibb Company
Boehringer Ingeiheim International GmbH
Bayer AG